BofA raised the firm’s price target on Biogen (BIIB) to $207 from $189 and keeps a Neutral rating on the shares post the Q4 report. The firm attributes the post-earnings share rally to “clear positives” from the call, including “not as bad as feared erosion” of the multiple sclerosis franchise, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target raised to $190 from $156 at Morgan Stanley
- Biogen price target raised to $215 from $185 at Citi
- Biogen: Solid Near-Term Execution but High-Risk Pipeline Keeps Rating at Hold
- Biogen: Limited Near-Term Growth and Execution Risks Justify Neutral Hold Rating
- Biogen Earnings Call: Solid 2025, Cautious 2026 Outlook